Darunavir analog precursors target mitochondrial metabolism in multiple myeloma and CLL.

ABSTRACT:

Background

Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) are hematological malignancies with poor prognosis due to drug resistance, with no effective therapies. Drug resistance occurs from alterations in microenvironment and metabolism. Impaired mitochondrial metabolism underlies drug resistance in MM and CLL, and drugs targeting mitochondrial respiration show cytotoxicity and increase chemotherapy sensitivity. HIV protease inhibitors like nelfinavir show antitumor activity and resensitize drug-resistant cells to bortezomib and venetoclax. We evaluated effects of two HIV protease inhibitor precursors, BupM-NH2 and BnpM-NH2, on MM and CLL cells and their mechanism.

Methods

The cytotoxicity of the compounds was evaluated in MM (MM1S and RPMI-8226) and CLL (HG3)

SUBMITTER: Mecca M 

PROVIDER: S-EPMC12838486 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature